Compounding Internet/Telehealth Surveillance Program Undercover Access
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 511210 Software Publishers
- Points of contact
-
- Christopher Scott christopher.scott@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration (FDA) is seeking to procure secure internet research licenses for the Office of Compliance in CDER, enabling covert surveillance of online drug marketplaces and digital platforms. The primary objective is to obtain undercover access capabilities for monitoring illegal drug-related activities, such as counterfeit medications and unauthorized compounding, with an estimated solicitation release date of December 1, 2025, and a projected contract award date of February 1, 2026. The contract falls under the Software Publishers NAICS code 511210 and is classified as a new requirement with no specific set-aside.
The point of contact for this forecasted opportunity is Christopher Scott, who can be reached at christopher.scott@fda.hhs.gov within the Food and Drug Administration organization. While specific award values or budget ranges are not currently available, the contract aims to provide comprehensive digital surveillance tools that enable anonymous research and evidence collection to support the FDA's public health protection mission. The research capabilities will focus on comprehensive monitoring across internet platforms, including social media, e-commerce sites, and online drug marketplaces, with the intent of preserving evidence integrity during investigative processes.
Forecast text
The Office of Compliance in CDER requests authorization to obtain licenses that enable secure internet research capabilities without disclosing FDA identity, which is essential for effective surveillance of drug-related illegal activities (e.g. counterfeit medications and unauthorized compounding) and protection of public health. Secure research capabilities would enable comprehensive monitoring of online drug marketplaces, social media platforms, and e-commerce sites. Anonymous access is critical for preserving evidence integrity. These covert capabilities are essential tools for CDER's Office of Compliance to fulfill its mission of protecting public health through effective drug regulation and enforcement in the digital age.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast